Prior to releasing the 5M product, Illumina will release an intermediate 2.5M product that adds rare variants to the strong backbone of content currently on the HumanOmni1-Quad BeadChip. The Infinium platform allows rapid evolution of GWAS products, said Jay Flatley, president and CEO of Illumina. Our genotyping product portfolio is regularly updated with the latest content to provide our customers with the most powerful analysis possible across populations and variant classes, all in one assay.

Researchers who begin studies now using Illumina ™s whole-genome genotyping products will have exclusive access to supplemental arrays that build from the Omni content to the full 5M variants. Customers on this preferred path will have the ability to incrementally interrogate novel sets of SNPs as they are released into public databases, prior to the release of the full 5M variant array. As with Illumina ™s previous whole-genome genotyping arrays, the new products will offer the high performance necessary for robust CNV detection, together with greater density of coverage enabling association of rare variants with diseases or traits.

illumina/